Spero Therapeutics (NASDAQ:SPRO) received a $30.00 target price from research analysts at Oppenheimer in a research note issued to investors on Thursday. The firm presently has a “buy” rating on the stock. Oppenheimer’s price target would indicate a potential upside of 150.21% from the stock’s current price.

Other analysts have also recently issued research reports about the stock. Bank of America assumed coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued a “neutral” rating on the stock. Stifel Nicolaus assumed coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued a “buy” rating and a $26.00 target price on the stock. Finally, Cowen assumed coverage on shares of Spero Therapeutics in a research note on Monday, November 27th. They issued an “outperform” rating on the stock.

Shares of Spero Therapeutics (NASDAQ:SPRO) opened at $11.99 on Thursday. The firm has a market cap of $172.29 and a PE ratio of -4.21. Spero Therapeutics has a 52 week low of $9.84 and a 52 week high of $15.40.

Spero Therapeutics (NASDAQ:SPRO) last posted its earnings results on Thursday, December 14th. The company reported ($36.02) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.43) by ($33.59). The company had revenue of $0.60 million for the quarter, compared to analyst estimates of $0.20 million. equities analysts anticipate that Spero Therapeutics will post -8.52 earnings per share for the current fiscal year.

In other news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of Spero Therapeutics stock in a transaction on Monday, November 6th. The shares were purchased at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Casper Breum purchased 214,285 shares of Spero Therapeutics stock in a transaction on Monday, November 6th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $2,999,990.00. The disclosure for this purchase can be found here. In the last three months, insiders purchased 649,356 shares of company stock worth $9,090,984.

TRADEMARK VIOLATION NOTICE: “Spero Therapeutics (SPRO) Given a $30.00 Price Target at Oppenheimer” was posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/spero-therapeutics-spro-given-a-30-00-price-target-at-oppenheimer/1802880.html.

About Spero Therapeutics

SmartPros Ltd. is engaged in provision of learning and educational solutions in content areas that target specific markets, including accounting/finance, legal, engineering, securities and insurance. The Company also provides education in banking, finance, taxation, information technology, health and safety, human resources and compliance for the general corporate market.

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.